Literature DB >> 20614220

Clusterin immunoexpression and its clinical significance in patients with non-small cell lung cancer.

Hecheng Li1, Shilei Liu, XiaoLi Zhu, Shuo Yang, Jiaqing Xiang, Haiquan Chen.   

Abstract

Clusterin is an enigmatic glycoprotein with a nearly ubiquitous tissue distribution. It plays important roles in various pathophysiological processes, including tissue remodeling, reproduction, lipid transport, complement regulation, and apoptosis. Clusterin appears to have two main isoforms that result from alternative splicing. The secreted and nuclear forms of clusterin have been reported to play different roles in human malignancies. The purpose of this study was to examine clusterin immunoexpression and its clinical significance in a group of Chinese patients with non-small cell lung cancer (NSCLC). Tissue samples from the primary tumors of 121 patients with completely resected NSCLC were obtained. Clusterin protein expression was evaluated by immunohistochemical staining with an antibody against all clusterin isoforms. Staining patterns were observed and graded based on intensity and density and were correlated with clinical and pathological data. Both cytoplasmic and nuclear clusterin immunostaining patterns were observed. Clusterin staining was observed only in the cytoplasm in 70 patients (57.9%), only in the nucleus in 27 patients (22.3%), and in both the cytoplasm and nucleus in 16 patients (13.2%). A significant association was observed between positive cytoplasmic clusterin expression and histologic type as indicated by adenocarcinomas that were more likely to have clusterin staining only in the cytoplasm. Clusterin immunostaining was neither associated with recurrence-free survival (RFS) nor overall survival of patients by univariate or multivariate analysis. For patients undergoing chemotherapy, those with only cytoplasmic clusterin staining had worse survival than other patients. In conclusion, both cytoplasmic and nuclear immunostaining patterns of clusterin were detected in the tumors of patients with NSCLC. Adenocarcinomas were more likely to have only cytoplasmic staining. The immunoexpression of clusterin was not associated with prognosis, and cytoplasm-only immunostaining of clusterin was inversely correlated with chemosensitivity in this group of patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20614220     DOI: 10.1007/s00408-010-9248-1

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  25 in total

1.  Expression of the secreted form of clusterin protein in renal cell carcinoma as a predictor of disease extension.

Authors:  Toshifumi Kurahashi; Mototsugu Muramaki; Kazuki Yamanaka; Isao Hara; Hideaki Miyake
Journal:  BJU Int       Date:  2005-10       Impact factor: 5.588

2.  Value of clusterin immunoreactivity as a predictive factor in muscle-invasive urothelial bladder carcinoma.

Authors:  Stefan Krüger; Anne Mahnken; Ingo Kausch; Alfred C Feller
Journal:  Urology       Date:  2006-01       Impact factor: 2.649

3.  Nuclear clusterin/XIP8, an x-ray-induced Ku70-binding protein that signals cell death.

Authors:  C R Yang; K Leskov; K Hosley-Eberlein; T Criswell; J J Pink; T J Kinsella; D A Boothman
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

4.  Expression of clusterin in human pancreatic cancer.

Authors:  Min-Jue Xie; Yoshiharu Motoo; Shi-Bing Su; Hisatsugu Mouri; Koushiro Ohtsubo; Fujitsugu Matsubara; Norio Sawabu
Journal:  Pancreas       Date:  2002-10       Impact factor: 3.327

5.  Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2'-O-(2-methoxy)ethyl chemistry.

Authors:  T Zellweger; H Miyake; S Cooper; K Chi; B S Conklin; B P Monia; M E Gleave
Journal:  J Pharmacol Exp Ther       Date:  2001-09       Impact factor: 4.030

6.  Cancer statistics, 1998.

Authors:  S H Landis; T Murray; S Bolden; P A Wingo
Journal:  CA Cancer J Clin       Date:  1998 Jan-Feb       Impact factor: 508.702

Review 7.  Clusterin: physiologic and pathophysiologic considerations.

Authors:  M E Rosenberg; J Silkensen
Journal:  Int J Biochem Cell Biol       Date:  1995-07       Impact factor: 5.085

8.  Intracellular clusterin induces G2-M phase arrest and cell death in PC-3 prostate cancer cells1.

Authors:  Maurizio Scaltriti; Anna Santamaria; Rosanna Paciucci; Saverio Bettuzzi
Journal:  Cancer Res       Date:  2004-09-01       Impact factor: 12.701

9.  Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo.

Authors:  Laura V July; Eliana Beraldi; Alan So; Ladan Fazli; Kenneth Evans; John C English; Martin E Gleave
Journal:  Mol Cancer Ther       Date:  2004-03       Impact factor: 6.261

10.  Intracellular clusterin causes juxtanuclear aggregate formation and mitochondrial alteration.

Authors:  Laure Debure; Jean-Luc Vayssiere; Vincent Rincheval; Fabien Loison; Yves Le Drean; Denis Michel
Journal:  J Cell Sci       Date:  2003-06-10       Impact factor: 5.285

View more
  8 in total

1.  Downregulating sCLU enhances the sensitivity of hepatocellular carcinoma cells to gemcitabine by activating the intrinsic apoptosis pathway.

Authors:  Peng Xiu; Zongzhen Xu; Feng Liu; Ziqiang Li; Tao Li; Fang Zou; Xueying Sun; Jie Li
Journal:  Dig Dis Sci       Date:  2014-03-27       Impact factor: 3.199

2.  Potential use of custirsen to treat prostate cancer.

Authors:  Celestia S Higano
Journal:  Onco Targets Ther       Date:  2013-06-25       Impact factor: 4.147

3.  Prognostic Role of Secretory Clusterin in Multiple Human Malignant Neoplasms: A Meta-Analysis of 26 Immunohistochemistry Studies.

Authors:  Jianzhong Zhang; Chenkui Miao; Aiming Xu; Kai Zhao; Zhiqiang Qin; Xiao Li; Chao Liang; Yibo Hua; Wei Chen; Chao Zhang; Yiyang Liu; Shifeng Su; Zengjun Wang; Bianjiang Liu
Journal:  PLoS One       Date:  2016-08-17       Impact factor: 3.240

4.  Aberrant fucosylation enables breast cancer clusterin to interact with dendritic cell-specific ICAM-grabbing non-integrin (DC-SIGN).

Authors:  Antonela Merlotti; Alvaro López Malizia; Paula Michea; Pierre-Emmanuel Bonte; Christel Goudot; María Sol Carregal; Nicolás Nuñez; Christine Sedlik; Ana Ceballos; Vassili Soumelis; Sebastián Amigorena; Jorge Geffner; Eliane Piaggio; Juan Sabatte
Journal:  Oncoimmunology       Date:  2019-06-24       Impact factor: 8.110

Review 5.  The multiple roles and therapeutic potential of clusterin in non-small-cell lung cancer: a narrative review.

Authors:  Juofang Tan; Wei Guo; Su Yang; Dingpei Han; Hecheng Li
Journal:  Transl Lung Cancer Res       Date:  2021-06

6.  Clinical significance of clusterin expression in pancreatic adenocarcinoma.

Authors:  Junshuo Jin; Joon-Mee Kim; Yoon-Seok Hur; Won Pyo Cho; Keon-Young Lee; Seung-Ik Ahn; Kee Chun Hong; In-Sun Park
Journal:  World J Surg Oncol       Date:  2012-07-16       Impact factor: 2.754

7.  Knockdown of clusterin sensitizes pancreatic cancer cells to gemcitabine chemotherapy by ERK1/2 inactivation.

Authors:  Yong Tang; Fenghua Liu; Chunning Zheng; Shaochuan Sun; Yingsheng Jiang
Journal:  J Exp Clin Cancer Res       Date:  2012-09-11

8.  Secretory Clusterin Mediates Oxaliplatin Resistance via the Gadd45a/PI3K/Akt Signaling Pathway in Hepatocellular Carcinoma.

Authors:  Xin Wang; Fang Zou; Jingtao Zhong; Longtao Yue; Fuhai Wang; Honglong Wei; Guangsheng Yang; Tao Jin; Xiaofeng Dong; Jie Li; Peng Xiu
Journal:  J Cancer       Date:  2018-04-06       Impact factor: 4.207

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.